Syn2bio (S2B) Stock Overview

Operates as a biotechnology company. More details

S2B fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the Polish market

S2B Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW482,450 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

482,450 investors already sharing narratives

View all narratives

Syn2bio S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Syn2bio
Historical stock prices
Current Share Price	zł80.06
52 Week High	zł96.60
52 Week Low	zł26.20
Beta	0
1 Month Change	135.47%
3 Month Change	124.26%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	124.26%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	S2B	PL Medical Equipment	PL Market
7D	26.1%	0.4%	3.2%
1Y	n/a	25.1%	28.4%

Return vs Industry: Insufficient data to determine how S2B performed against the Polish Medical Equipment industry.

Return vs Market: Insufficient data to determine how S2B performed against the Polish Market.

Price Volatility

Is S2B's price volatile compared to industry and market?
S2B volatility
S2B Average Weekly Movement	15.3%
Medical Equipment Industry Average Movement	6.6%
Market Average Movement	5.1%
10% most volatile stocks in PL Market	10.4%
10% least volatile stocks in PL Market	3.0%

Stable Share Price: S2B's share price has been volatile over the past 3 months compared to the Polish market.

Volatility Over Time: Insufficient data to determine S2B's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2025	n/a	Cezary Kozanecki	syn2bio.pl/en

Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It also engages in the research of new pharmaceutical compounds and its further study, registration, and market launch as a medicinal product.

Syn2bio S.A. Fundamentals Summary

How do Syn2bio's earnings and revenue compare to its market cap?
S2B fundamental statistics
Market cap	zł698.85m
Earnings (TTM)	zł0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is S2B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
S2B income statement (TTM)
Revenue	zł0
Cost of Revenue	zł0
Gross Profit	zł0
Other Expenses	zł0
Earnings	zł0

Last Reported Earnings

n/a

Next Earnings Date

Aug 13, 2026

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did S2B perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/15 03:12
End of Day Share Price	2026/07/15 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syn2bio S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku